PREVIEW OF MEDICAL SCIENCE LIAISONS IN ONCOLOGY

MEDICAL SCIENCELIAISONS INONCOLOGY (2016)

M A R C H , 2 0 1 6

P R E V I E W O F

REPORT OVERVIEW

HOW YOU CAN USE THIS REPORT

Biopharmaceutical research companies efforts to bring new, more effective treatments to market represent the world’s best hopes to provide oncologists with the drugs needed to give cancer patients longer, healthier lives and reduce the burden of the disease on society. To garner awareness, interest, and trial for any of oncological medications in development in the highly competitive US cancer drug market, biopharmaceutical manufacturers must develop sales/ information strategies that best serve oncologists’ needs. These strategies will certainly employ Medical Science Liaisons (MSLs) in addition to traditional sales representatives. ISR’s Medical Science Liaison in Oncology offers insights into how oncologists engage with 20 biopharmaceutical manufacturer’s MSLs. This report contains critical knowledge on how manufacturers can best engage oncologists in a drug’s story.

153 PAGES

20COMPANIES

Introduction

SMARTER QUESTIONS SMARTER ANSWERS

MAJOR SECTIONS:1. Access to Oncologists

2. MSL Performance

3. The MSL InteractionExperience

4. Information Strategies

5. Study Data

Full list of companies included on next page.

• Understand how US oncologists want to be engaged

• Learn how likely oncologists are to accept a meeting with a sales rep or an MSL to discuss a new product

• Discover the traits of the best MSLs, and which biopharmaceutical firms field MSLs exceed orfail to meet oncologists’ expectations

• Uncover what type of interactions oncologists view as appropriate and effective boundaries not to cross when engaging with an oncologist.

• Pinpoint the information oncologists find most valuableand the best channels for delivering specific types ofdata/ information

D A T A C O L L E C T I O N I N Q 1 , 2 0 1 6

3 0 - M I N U T E W E B - B A S E D

S U R V E Y

1 0 1 O N C O L O G I S T S F R O M U S , E U R O P E ,

A N D A S I A

http://isrreports.com

COMPANIES INCLUDED

ATTRIBUTES MEASURED

AbbVie

Amgen

Astellas

AstraZeneca

Bayer

Bristol-Myers Squibb

Celgene

Eisai

Eli Lilly

GSK

Incyte

Johnson & Johnson

Merck & Co.

Novartis

Otsuka

Pfizer

Pharmacyclics

Roche

Sanofi

Takeda

Introduction


KNOWLEDGE FACTORS• Knowledge of science• Knowledge of the current clinical trial

environment• Knowledge of the regulatory

environment• Knowledge of the reimbursement

environment• Knowledge of what drives success in

your practice

SERVICE FACTORS• Being responsive to your needs• Creating value for your practice• Delivering great service• Putting your needs first• Treating you as a peer/ partner in

patient care

each company is evaluated

based on 10 CRITICAL ATTRIBUTES

data are included for all 20

manufacturers, but companies

with more than 10

performance evaluations

(bold) receive a full profile

Companies listed bold have been reviewed by 10 or more respondents. These providers have in-depth performance analysis.


Introduction


TABLE OF CONTENTSCOPYRIGHT AND USAGE GUIDELINES

INTRODUCTION

METHODOLOGY

Respondent Profile

Practice Area

Years in Practice

Types of Cancer Treated

Primary Practice Setting

Last MSL or Sales Rep Visit

Number of Ratings per Company

STUDY FINDINGS

ACCESS TO ONCOLOGISTS

Primary Findings

Opportunities for Access

Restriction Level

Restrictions on Detailing

MSL versus Rep versus eDetail

Information of Most Interest to Oncologists

Preferred MSL Traits

Visit Activity

Recent Visit Activity

Visit Duration

Firms Visiting Oncologists in Past 12 Months

MSL PERFORMANCE

Primary Findings

Best MSLs

Satisfaction with Interactions

THE MSL INTERACTION EXPERIENCE

Primary Findings

Discussion Topics

Typical Topics Discussed

Value of Topics Discussed

Appropriateness of Topics Discussed

INFORMATION STRATEGIES

Primary Findings

Preferred Source of Information

Categories of Information

Learning About Different Data Types

Data Source Influence on Prescribing Decisions

Influence of Presentation Frequency on Prescribing Decisions

Networking Role and Value

MSL Outsourcing

MSL Clinical Trial Involvement

STUDY DATA

Professional Profile

Practice Area

Years in Practice

Types of Cancer Treated

Primary Practice Setting

Patient Volume

Direct Patient Care

Professional Perception

Influence on Others Practicing Oncology

MSL and Sales Representative Interactions

Pharmaceutical Sales Representative Interaction Restrictions

Restrictions on Pharmaceutical Sales Representative Detailing

Restrictions on Pharmaceutical Sales Representative Detailing – Verbatim Comments

Most Recent Pharmaceutical Sales Representative Detail

Satisfaction with Pharmaceutical Sales Representative Interactions

Pharmaceutical Sales Representative Detail Duration with Oncologist

Pharmaceutical Sales Representative Detail Duration with Oncology Practice Manager

MSL Restriction Level

Restrictions on MSL Detailing

Restrictions on MSL Detailing – Verbatim Responses

Most Recent MSL Detail

Typical Topics Discussed

Typical Topics Discussed – Verbatim Comments

Firms Calling in Past 12 Months

Satisfaction with MSL Interactions – Categories

Satisfaction with MSL Interactions – Mean Ratings


Introduction


MSL Detail Duration with Oncologist

MSL Detail Duration with Oncology Practice Manager

Best MSLs

Information of Interest to Oncologists

Information of Interest to Oncologists – Verbatim Comments

Appropriateness of Topics Discussed

Networking Role and Value

Preferred MSL Traits

Assessing MSL Performance

Accepting Meeting to Discuss First-in-Class Oncology Product

Accepting Meeting to Discuss a Novel MOA

Accepting Meeting to Discuss a Transitional or Follow-on Oncology Product

Preferred Information Delivery Method

Data Presentation Frequency

Information Type Influence on Prescribing

Preferred Information Type by Presenter

MSL Performance Drill-Down

AbbVie

Amgen

Astellas

AstraZeneca

Bayer


Celgene

Eisai

Eli Lilly

GSK

Incyte

Johnson & Johnson

Merck & Co.

Novartis

Otsuka

Pfizer

Pharmacyclics

Roche

Sanofi

Takeda

Prescribing Flexibility

Influence of Private Payers on Prescribing

Influence of State and Federal Government Payers on Prescribing

Future Prescribing Environment

Future Prescribing Environment – Verbatim Responses

Insurance Programs

Awareness of Insurance Incentive Programs

Insurance Incentive Program Benefits

Insurance Incentive Program Benefits – Verbatim Responses

Insurance Incentive Program Drawbacks

Insurance Incentive Program Drawbacks – Verbatim Responses

Impact of Affordable Care Act on Practice

Impact of Affordable Care Act on Practice – Verbatim Responses

Accountable Care Organization (ACO) Status

MSL Outsourcing

MSL Outsourcing – Verbatim Responses

MSL Clinical Trial Involvement

ABOUT INDUSTRY STANDARD RESEARCH

117CHARTS

AND GRAPHS

SAMPLE PAGES

TABLE OF CONTENTS


Introduction


STUDY FINDINGS

14www.ISRreports.com ©2016 Medical Science Liaisons in Oncology (2016)

Restrictions on DetailingThe restrictions oncology practices/ organizations place on MSLs and sales reps do not appear to be overly burdensome� Many practices/ organizations require MSLs to set-up an appointment (52%) or restrict the duration/ number/ location of meetings (31%)�

Sales reps are substantially more likely to face restrictions on offering meals, gifts, or financial benefits to oncologists and the practice (27%) than MSLs, who, by definition, serve as scientific or disease state experts for oncologists� It is worth noting that one-in-ten (10%) oncology practices/ organizations require MSLs to demonstrate a non-sales agenda in order to gain access to oncologists�

Please describe any and all restrictions your practice/ organization has regarding the interactions with MSLs (Medical Science Liaisons). (Base=29, restrictions on MSL detailing in place)

Please describe any and all restrictions your practice/ organization has regarding the interactions with pharmaceutical sales representatives. (Base=49, restrictions on sales rep detailing in place)

MEDICAL SCIENCE LIAISONS IN ONCOLOGY (2016) 16

Restrictions on Detailing The restrictions oncology practices/ organizations place on MSLs and sales reps do not appear to be overly burdensome. Many practices/ organizations require MSLs to set-up an appointment (52%) or restrict the duration/ number/ location of meetings (31%). Sales reps are substantially more likely to face restrictions on offering meals, gifts, or financial benefits to oncologists and the practice (27%) than MSLs, who, by definition, serve as scientific or disease state experts for oncologists. It is worth noting that one-in-ten (10%) oncology practices/ organizations require MSLs to demonstrate a non-sales agenda in order to gain access to oncologists. Please describe any and all restrictions your practice/ organization has regarding the interactions with MSLs (Medical Science Liaisons). (Base=29, restrictions on MSL detailing in place) Please describe any and all restrictions your practice/ organization has regarding the interactions with pharmaceutical sales representatives. (Base=49, restrictions on sales rep detailing in place)

2%

2%

16%

27%

33%

22%

3%

7%

10%

31%

52%

0% 20% 40% 60%

Cannot see reps but can see MSLs

Can only receive samples

Seeing reps/MSLs is permitted but isdiscouraged by practice management

No meals, gifts, financial benefit to oncologistor practice

MSL must demonstrate/ have a non-salesagenda

Restricted to specific duration/ Number ofmeetings per week or month/ Location in

practice

Must set-up an appointment

% of Respondents

MSLs

Sales Reps

© Industry Standard Research

This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR ([email protected]).

S A M P L E P A G E :

OPPORTUNITIES FOR ACCESS

ISR knows oncologists must manage their time wisely to treat patients, manage their business, and learn about new medications. In this report, ISR establishes the level of restrictions oncologists place between themselves and MSLs/ Pharmaceutical sales representatives. Data on visit recency and duration are also described. ISR also looks at oncologists preferred sales channel for receiving information about first-in-class medications, novel MOAs, and follow-on oncology products.

C L O S E R L O O K

Understand the various types of restrictions MSLs will face, from requirements to set up meeting times, to restrictions on duration and number of meetings, to the need to demonstrate a non-sales agenda

Learn more in the full report: www.ISRreports.com

STUDY FINDINGS


Restrictions on DetailingThe restrictions oncology practices/ organizations place on MSLs and sales reps do not appear to be overly burdensome� Many practices/ organizations require MSLs to set-up an appointment (52%) or restrict the duration/ number/ location of meetings (31%)�

Sales reps are substantially more likely to face restrictions on offering meals, gifts, or financial benefits to oncologists and the practice (27%) than MSLs, who, by definition, serve as scientific or disease state experts for oncologists� It is worth noting that one-in-ten (10%) oncology practices/ organizations require MSLs to demonstrate a non-sales agenda in order to gain access to oncologists�

Please describe any and all restrictions your practice/ organization has regarding the interactions with MSLs (Medical Science Liaisons). (Base=29, restrictions on MSL detailing in place)

Please describe any and all restrictions your practice/ organization has regarding the interactions with pharmaceutical sales representatives. (Base=49, restrictions on sales rep detailing in place)

MEDICAL SCIENCE LIAISONS IN ONCOLOGY (2016) 16

Restrictions on Detailing The restrictions oncology practices/ organizations place on MSLs and sales reps do not appear to be overly burdensome. Many practices/ organizations require MSLs to set-up an appointment (52%) or restrict the duration/ number/ location of meetings (31%). Sales reps are substantially more likely to face restrictions on offering meals, gifts, or financial benefits to oncologists and the practice (27%) than MSLs, who, by definition, serve as scientific or disease state experts for oncologists. It is worth noting that one-in-ten (10%) oncology practices/ organizations require MSLs to demonstrate a non-sales agenda in order to gain access to oncologists. Please describe any and all restrictions your practice/ organization has regarding the interactions with MSLs (Medical Science Liaisons). (Base=29, restrictions on MSL detailing in place) Please describe any and all restrictions your practice/ organization has regarding the interactions with pharmaceutical sales representatives. (Base=49, restrictions on sales rep detailing in place)

2%

2%

16%

27%

33%

22%

3%

7%

10%

31%

52%

0% 20% 40% 60%

Cannot see reps but can see MSLs

Can only receive samples

Seeing reps/MSLs is permitted but isdiscouraged by practice management

No meals, gifts, financial benefit to oncologistor practice

MSL must demonstrate/ have a non-salesagenda

Restricted to specific duration/ Number ofmeetings per week or month/ Location in

practice

Must set-up an appointment

% of Respondents

MSLs

Sales Reps




Introduction


STUDY FINDINGS


Preferred MSL TraitsA strong theme throughout this research is the oncologist’s view of an MSL as an expert resource for current and future patient treatment options� When asked about the one trait an MSL should have, oncologists want MSLs to be well-versed in how their manufacturer’s products fit into the disease state (29%, top choice)� Secondarily, MSLs must have a knowledge of ongoing and upcoming clinical trials�

Medical Science Liaisons (MSLs) are peer-level personnel whose main job is not to sell a product but rather to foster scientific and medical discussion and be a point of reference for disease education and management. With that in mind, which three traits would you most want an MSL to have? Please select 3. (Base=101)

Again, which one trait would you most want to an MSL to have? Select only one. (Base=101)

MEDICALSCIENCELIAISONSINONCOLOGY(2016) 19

Preferred MSL Traits A strong theme throughout this research is the oncologist’s view of an MSL as an expert resource for current and future patient treatment options. When asked about the one trait an MSL should have, oncologists want MSLs to be well-versed in how their manufacturer’s products fit into the disease state (29%, top choice). Secondarily, MSLs must have a knowledge of ongoing and upcoming clinical trials. Medical Science Liaisons (MSLs) are peer-level personnel whose main job is not to sell a product but rather to foster scientific and medical discussion and be a point of reference for disease education and management. With that in mind, which three traits would you most want an MSL to have? Please select 3. (Base=101) Again, which one trait would you most want to an MSL to have? Select only one. (Base=101)

17%

18%

19%

31%

25%

27%

33%

41%

47%

45%

2%

3%

5%

5%

8%

8%

12%

13%

16%

29%

0% 20% 40% 60%

Ability to gather and present KOL opinions

A broad and deep professional network, which you can leverage

High degree of knowledge around product pricing and reimbursement/ formulary

placements

Excellent communication skills; not only knowing what to say but how to say it

Knowledge of and solutions for patient-centric care, e.g. adherence, disease

education, treatment paradigms

Excellent analytical thinking skills

Expertise in separating "the signal from the noise" in order to provide relevant and

valuable information

Scientific knowledge of the mechanism of action (MOA) and the unique benefits and

risks of a single product

Knowledge of currently enrolling or upcoming clinical trials

Solid understanding of how a product fits into an overall disease-state approach

including competitive product knowledge

% of Respondents

Top Choice

Select 3




PREFERRED MSL TRAITSISR’s research shows that the oncologists view an MSL as an expert resource for current and future patient treatment options. The Medical Science Liaison in Oncology report asked oncologists to identify the single most important trait MSLs must possess to establish a working relationship with an oncologist.

The full data are available in the report, which can be downloaded from www.ISRreports.com.

D A T A I N F U L L R E P O R T

D A T A I N F U L L R E P O R T


Introduction


STUDY FINDINGS


Knowledge Factor

Ratings Key: Clear leadership Better than most About average Falling a bit short Likely deficiency

Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the

current trialenvironment

Knowledge of the

regulatory environment

Knowledge of the

reimbursementenvironment

Knowledge of what drives success in

your practice



SERVICE PROVIDER PERFORMANCEAs part of the “MSL Performance” section ISR provides an analysis of profiled companies’ service attribute ratings. This chart shows MSL knowledge characteristics, but the report also includes ratings for MSL service.

The full data are available in the report, which can be downloaded from www.ISRreports.com.

D A T A H A V E B E E N R A N D O M I Z E D . F U L L C H A R T A V A I L A B L E I N T H E R E P O R T .

Company A

Company B

Company C

Company D

Company E

Company F

Company G

Company H

Company I

Company J

Company K

Company L

Company M

STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice


STUDY FINDINGS


Knowledge Factor


Amgen

AstraZeneca

Bayer


Celgene

Eli Lilly

GSK

Johnson & Johnson

Merck & Co.

Novartis

Pfizer

Roche

Takeda

Knowledgeof

science

Knowledge of the


Knowledge of the


Knowledge of the



your practice



TO LEARN MORE: CONTACT US AT [email protected] OR +1(919)301-0106

Biosimilars & Biologics

Clinical Trial Recruitment &

Retention

Commercialization Department Models & Structures

Trends & Technologies

Manufacturing Service Provider Quality Benchmarking

CUSTOM RESEARCH

UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.

Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your

customer or potential customer base?

UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).

Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or

brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the

purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and

manage their loyalty over time?

CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE

S O M E T H I N G T O C O N S I D E R

DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.

UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization

AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.

LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:

mailto:[email protected]

Introduction


To obtain full access to this report, please select one of the following licenses:

To purchase the report with a credit card or invoice, simply click on the desired license above to be taken to the report page. If you’d like to inquire about a different payment method or have questions, contact us at [email protected] or +1.919.301.0106.

To schedule a call to discuss this report with one of our analysts, please e-mail us at [email protected].

ORDERING INFORMATION

SINGLE-USER LICENSE A single-user license allows access to a single individual user. $4,900 USD

SITE-WIDE LICENSE A site-wide license allows access to organization employees within a particular geographic site/location (i.e. NYC or London office).

$7,350 USD

ENTERPRISE-WIDE LICENSE

An enterprise-wide license allows access to ALL employees in an organization – this is the recommended license if a report has widespread relevance throughout an organization.

$9,800 USD

Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.

ABOUT INDUSTRY STANDARD RESEARCH

>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report

>>Earn 10% credit towards all future purchases

>>Receive advanced notifications on ISR’s latest reports and free resources

SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT




https://www.isrreports.com/industry-reports/purchase/social-media-best-practices-and-strategic-use-in-patient-recruitment/single

https://www.isrreports.com/industry-reports/purchase/social-media-best-practices-and-strategic-use-in-patient-recruitment/site

https://www.isrreports.com/industry-reports/purchase/social-media-best-practices-and-strategic-use-in-patient-recruitment/enterprise

https://www.isrreports.com/industry-reports/purchase/social-media-best-practices-and-strategic-use-in-patient-recruitment/enterprise

www.ISRreports.com


https://twitter.com/ISRreports

http://www.isrreports.com/register/

Introduction


www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 11

act with confidence

www.ISRreports.com ©2015 | Preview of: Epithelial Ovarian Cancer: Disease and Pipeline Analysis 10

act with confidence


act with confidence

www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 10

act with confidence


act with confidence

The ISR DifferenceCustom-quality syndicated market research

www.ISRreports.com

ISR's Reports The Common Syndicated Reportvs.

How confident are you?

vs.Data Collection

ISR's proprietary data collection tools and channels support fast,

high quality data collection

Struggle to recruit the right targets and enough of them

vs.Sample Sizes

Robust sample sizes that instill confidence

Often insufficient industry representation that leaves you

defending results

vs.vs.Research methods

Mostly primary research;

always appropriate for the topic

One size fits all; usually publically

available data

vs.vs.Respondents

Sophisticated screening ensures genuine decision-makers

Undisclosed methodologies and

respondent demographics

vs.vs.Analysts

Decades of experience means more insights that are

immediately usable

Junior analysts capable of reporting numbers


www.ISRreports.com

http://www.isrreports.com

Documents

PREVIEW OF MEDICAL SCIENCE LIAISONS IN ONCOLOGY